Maa: Singapore
Kieli: englanti
Lähde: HSA (Health Sciences Authority)
MEFLOQUINE HCl EQV MEFLOQUINE BASE
ROCHE SINGAPORE PTE. LTD.
P01BC02
250 mg
TABLET
ORAL
Pharmacy Only
F HOFFMANN-LA ROCHE LTD
1992-11-25
LARIAM® Mefloquine hydrochloride 1. DESCRIPTION 1.1 THERAPEUTIC / PHARMACOLOGIC CLASS OF DRUG Antimalarial 1.2 TYPE OF DOSAGE FORM Tablets (cross-scored) 250 mg 1.3 ROUTE OF ADMINISTRATION Oral 1.4 QUALITATIVE AND QUANTITATIVE COMPOSITION One cross-scored tablet contains: _Active ingredient_: 274.09 mg racemic mefloquine hydrochloride, equivalent to 250 mg mefloquine base. _Excipients_: poloxamer 3800, microcrystalline cellulose, lactose, maize starch, crospovidone, ammonium calcium alginate, talc and magnesium stearate. 2. CLINICAL PARTICULARS 2.1 THERAPEUTIC INDICATION(S) Prophylaxis, therapy and stand-by treatment of malaria. _Prophylaxis:_ Chemoprophylaxis with Lariam is recommended for travelers to malarious areas, particularly those traveling to areas where there is a high risk of infection with strains of _P. falciparum_ resistant to other antimalarials. _Therapy:_ Lariam is indicated for the oral treatment of malaria, particularly when caused by strains of _P. falciparum_ resistant to other antimalarials. It may also be used for the treatment of _P. vivax_ and mixed malaria (see 2.2 Dosage and Administration). _Stand-by treatment:_ Lariam is also prescribed as a stand-by medication, to be carried by the traveler and self-administered as an emergency measure for suspected malaria when prompt medical attention is unavailable within 24 hours. 2.2 DOSAGE AND ADMINISTRATION Mefloquine has a bitter and slightly burning taste. Lariam tablets should be swallowed whole, with at least one glass of liquid. The tablets may be crushed and suspended in a small amount of water, milk or other beverage for administration to small children and other persons unable to swallow them whole. 1 _PROPHYLAXIS STANDARD DOSAGE _ The recommended prophylactic dose of La Lue koko asiakirja